1. Home
  2. WNEB vs AKBA Comparison

WNEB vs AKBA Comparison

Compare WNEB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$13.70

Market Cap

264.8M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.87

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
AKBA
Founded
1853
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.8M
251.0M
IPO Year
2001
2014

Fundamental Metrics

Financial Performance
Metric
WNEB
AKBA
Price
$13.70
$0.87
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$13.67
$4.67
AVG Volume (30 Days)
30.6K
4.9M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
2.00%
N/A
EPS Growth
33.93
93.94
EPS
0.24
N/A
Revenue
$44,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.25
N/A
P/E Ratio
$56.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.53
$0.88
52 Week High
$14.52
$4.08

Technical Indicators

Market Signals
Indicator
WNEB
AKBA
Relative Strength Index (RSI) 57.53 30.47
Support Level $13.60 $0.88
Resistance Level $14.22 $1.56
Average True Range (ATR) 0.47 0.06
MACD 0.05 0.00
Stochastic Oscillator 89.05 22.27

Price Performance

Historical Comparison
WNEB
AKBA

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: